Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 17Other hematologic neoplasm 4Breast 4Sarcoma 2Plasma cell 2Gynecologic 2Gastrointestinal 2CNS 2Myeloid 1Head & Neck 1Dermatologic 1

Conditions

Leukemia 7Myelodysplastic Syndromes 5Primary Myelofibrosis 3Polycythemia Vera 3Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Thrombocythemia, Essential 1Splenomegaly 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Iron Deficiencies 1Anemia, Aplastic 1Anemia 1

Interventions

Cyclophosphamide 88fludarabine phosphate 77Busulfan 56Tacrolimus 54Mycophenolic Acid 54Antilymphocyte Serum 48Peripheral Blood Stem Cell Transplantation 46Filgrastim 42Melphalan 41Cyclosporine 39Whole-Body Irradiation 38fludarabine 36Radiotherapy 32Methotrexate 28Cord Blood Stem Cell Transplantation 25Methylprednisolone 24Alemtuzumab 17Etoposide 16Thiotepa 15Rituximab 14Cytarabine 14thymoglobulin 13Granulocyte Colony-Stimulating Factor 12Stem Cell Transplantation 10sargramostim 9Sirolimus 9Flow Cytometry 9Psychiatric Rehabilitation 8Prednisone 7Mesna 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Surveys and Questionnaires × Myeloid × Clear all
NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡